bank region banking- nim
expans may less benefici due lag loan beta
cardio cardio- coapt strongli posit interest
leisur product august equip sale yoy
midstream oil ga midstream thought self-fund
eli lilli compani kansa citi denver west
youssef squali nave khan idm kansa citi
buy consist king buy reiter buy
rais pt ebitda
believ investor increasingli appreci fidel consist
organ revenue growth scalabl outperform
lag faster grow peer
believ mean revert growth valuat appear
stretch fidel consist appeal growth
deceler make macro call rather highlight
compel risk/reward remain confid low-
to-mid singl organ revenue growth compound
thesi intact post-investor meet rais pt
maintain posit view rais pt
follow recent investor meet
greater comfort abil execut
target ebitda believ current momentum
could carri potenti enhanc sharehold
return within next month buy michael swartz
econ model reveal materi upsid potenti pt
trade ev/sal believ market
multipl reflect long term opportun growth free
cash flow may evid current street estim
accordingli set understand long term potenti
busi model individu growth driver unit
basi applic although outcom
scenario wide valuat low-end
valuat high-end blend view see potenti
materi upsid lead us increas pt
reiter buy rate sandi draper
broadcom limit buy note
road buy under-valu grower get paid way
tom kraus cfo despit recoveri
pre-ca level believ investor skeptic abound around
organ growth strategi disclosur
expect organ growth sale hsd ep
drive solid doubl digit ep growth last yr
ep grew compound-annual-growth-rate pf ep core
ca believ model worth
mitral repair set function mitral regurgit
favor bend clinic trajectori especi
import structur heart pure-play edward lifesci
ew buy strong coapt result context
neg mitra-fr trial rais interest question clinic
segment clinic trial design rel merit mitral
thesi intact post-investor meet rais pt
maintain posit view rais pt
follow recent investor meet
greater comfort abil execut
target ebitda believ current momentum
could carri potenti enhanc sharehold
return within next month buy michael swartz
consum stapl last week wheat price increas
higher wheat price could neg impact
compani univers
 william chappel jr stephani
electr power util
electr power util power/util macro trend
includ analysi key macro factor impact
dark spread gas/coal spread trend domest electr
consumpt growth nation weather pattern base
latest peer group valuat chang price target
 ali agha
weekli sector comparison compani includ
wrd neal dingmann well
midstream oil ga tristan richardson
bank region fed like
hike rate septemb meet nim pressur could
increas due lower loan beta loan beta may
mute libor move much prior
last rate hike june asset sensit bank
stronger core deposit base like
page
experi less nim pressur view jennif demba
estim revis guidanc expect impact capit
action reduc core ep estim
reflect net impact
prefer equiti issuanc increas share repurchas
author weaker net interest incom guidanc
capit action could provid approxim lift ep
weaker fundament outlook could weigh earn
per share michael young
econ model reveal materi upsid potenti pt
trade ev/sal believ market
multipl reflect long term opportun growth free
cash flow may evid current street estim
accordingli set understand long term potenti
busi model individu growth driver unit
basi applic although outcom
scenario wide valuat low-end
valuat high-end blend view see potenti
materi upsid lead us increas pt
reiter buy rate sandi draper
mitral repair set function mitral regurgit
favor bend clinic trajectori especi
import structur heart pure-play edward lifesci
ew buy strong coapt result context
neg mitra-fr trial rais interest question clinic
segment clinic trial design rel merit mitral
inc buy continu progress
cardiogen shock increas focu renal protect
superior zilver ptx bruce nudel
luxturna receiv posit opinion chmp edward nash
earn plan initi ridinilazol cdi data
expect summit report earn updat
pipelin develop fail phase ii studi ezutromid
dmd summit focus antibiot lead asset
ridinilazol cdi plan phase initi
data expect summit also recent nomin
progress ind-en studi gonorrhea
phase initi expect maintain hold
page
rate pt given lack near-term catalyst
weak-perform antibiot space edward nash
result wednesday septemb open
earn call et estim price target
buy consist king buy reiter buy
rais pt ebitda
believ investor increasingli appreci fidel consist
organ revenue growth scalabl outperform
lag faster grow peer
believ mean revert growth valuat appear
stretch fidel consist appeal growth
deceler make macro call rather highlight
compel risk/reward remain confid low-
to-mid singl organ revenue growth compound
improv may horizon recent visit
headquart houston opportun
meet manag entir staff follow key
broadcom limit buy note
road buy under-valu grower get paid way
tom kraus cfo despit recoveri
pre-ca level believ investor skeptic abound around
organ growth strategi disclosur
